|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KAT5 |
Gene summary for KAT5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KAT5 | Gene ID | 10524 |
| Gene name | lysine acetyltransferase 5 | |
| Gene Alias | ESA1 | |
| Cytomap | 11q13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q92993 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10524 | KAT5 | P4_S8_cSCC | Human | Skin | cSCC | 1.56e-06 | 1.14e-01 | -0.3095 |
| 10524 | KAT5 | P5_S10_cSCC | Human | Skin | cSCC | 1.30e-02 | 2.08e-02 | -0.299 |
| 10524 | KAT5 | P1_cSCC | Human | Skin | cSCC | 5.06e-23 | 6.76e-01 | 0.0292 |
| 10524 | KAT5 | P2_cSCC | Human | Skin | cSCC | 1.05e-16 | 3.66e-01 | -0.024 |
| 10524 | KAT5 | P4_cSCC | Human | Skin | cSCC | 6.63e-23 | 4.18e-01 | -0.00290000000000005 |
| 10524 | KAT5 | P10_cSCC | Human | Skin | cSCC | 1.15e-21 | 5.41e-01 | 0.1017 |
| 10524 | KAT5 | cSCC_p9 | Human | Skin | cSCC | 4.33e-05 | 6.03e-02 | -0.1991 |
| 10524 | KAT5 | male-WTA | Human | Thyroid | PTC | 1.10e-15 | 1.15e-01 | 0.1037 |
| 10524 | KAT5 | PTC01 | Human | Thyroid | PTC | 2.71e-11 | 2.63e-01 | 0.1899 |
| 10524 | KAT5 | PTC04 | Human | Thyroid | PTC | 3.84e-17 | 2.67e-01 | 0.1927 |
| 10524 | KAT5 | PTC05 | Human | Thyroid | PTC | 1.79e-16 | 5.58e-01 | 0.2065 |
| 10524 | KAT5 | PTC06 | Human | Thyroid | PTC | 1.56e-24 | 5.08e-01 | 0.2057 |
| 10524 | KAT5 | PTC07 | Human | Thyroid | PTC | 3.91e-31 | 4.35e-01 | 0.2044 |
| 10524 | KAT5 | ATC09 | Human | Thyroid | ATC | 2.17e-03 | 1.86e-01 | 0.2871 |
| 10524 | KAT5 | ATC11 | Human | Thyroid | ATC | 3.64e-02 | 2.62e-01 | 0.3386 |
| 10524 | KAT5 | ATC12 | Human | Thyroid | ATC | 3.27e-21 | 2.42e-01 | 0.34 |
| 10524 | KAT5 | ATC13 | Human | Thyroid | ATC | 2.84e-28 | 1.75e-01 | 0.34 |
| 10524 | KAT5 | ATC1 | Human | Thyroid | ATC | 5.52e-05 | 2.42e-01 | 0.2878 |
| 10524 | KAT5 | ATC2 | Human | Thyroid | ATC | 1.66e-03 | 2.98e-01 | 0.34 |
| 10524 | KAT5 | ATC3 | Human | Thyroid | ATC | 4.99e-02 | 1.99e-01 | 0.338 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
| GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:001050617 | Esophagus | ESCC | regulation of autophagy | 220/8552 | 317/18723 | 6.72e-18 | 6.36e-16 | 220 |
| GO:0072331111 | Esophagus | ESCC | signal transduction by p53 class mediator | 121/8552 | 163/18723 | 9.61e-14 | 4.69e-12 | 121 |
| GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
| GO:001021217 | Esophagus | ESCC | response to ionizing radiation | 110/8552 | 148/18723 | 1.11e-12 | 4.78e-11 | 110 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:004277014 | Esophagus | ESCC | signal transduction in response to DNA damage | 117/8552 | 172/18723 | 2.38e-09 | 5.32e-08 | 117 |
| GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
| GO:0030330110 | Esophagus | ESCC | DNA damage response, signal transduction by p53 class mediator | 53/8552 | 72/18723 | 1.34e-06 | 1.63e-05 | 53 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
| hsa0501728 | Esophagus | ESCC | Spinocerebellar ataxia | 94/4205 | 143/8465 | 6.77e-05 | 2.90e-04 | 1.48e-04 | 94 |
| hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
| hsa0501736 | Esophagus | ESCC | Spinocerebellar ataxia | 94/4205 | 143/8465 | 6.77e-05 | 2.90e-04 | 1.48e-04 | 94 |
| hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
| hsa0501725 | Oral cavity | OSCC | Spinocerebellar ataxia | 86/3704 | 143/8465 | 5.21e-05 | 2.08e-04 | 1.06e-04 | 86 |
| hsa05166113 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
| hsa05017111 | Oral cavity | OSCC | Spinocerebellar ataxia | 86/3704 | 143/8465 | 5.21e-05 | 2.08e-04 | 1.06e-04 | 86 |
| hsa05166210 | Oral cavity | LP | Human T-cell leukemia virus 1 infection | 100/2418 | 222/8465 | 8.94e-08 | 1.29e-06 | 8.35e-07 | 100 |
| hsa0501726 | Oral cavity | LP | Spinocerebellar ataxia | 59/2418 | 143/8465 | 6.97e-04 | 3.46e-03 | 2.23e-03 | 59 |
| hsa0516638 | Oral cavity | LP | Human T-cell leukemia virus 1 infection | 100/2418 | 222/8465 | 8.94e-08 | 1.29e-06 | 8.35e-07 | 100 |
| hsa0501735 | Oral cavity | LP | Spinocerebellar ataxia | 59/2418 | 143/8465 | 6.97e-04 | 3.46e-03 | 2.23e-03 | 59 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KAT5 | SNV | Missense_Mutation | novel | c.758N>A | p.Arg253Gln | p.R253Q | Q92993 | protein_coding | tolerated(0.61) | benign(0.206) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
| KAT5 | SNV | Missense_Mutation | c.1469N>A | p.Ser490Tyr | p.S490Y | Q92993 | protein_coding | tolerated(0.06) | possibly_damaging(0.689) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| KAT5 | SNV | Missense_Mutation | c.563N>T | p.Ser188Leu | p.S188L | Q92993 | protein_coding | tolerated(0.12) | benign(0.009) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
| KAT5 | SNV | Missense_Mutation | c.629G>A | p.Arg210His | p.R210H | Q92993 | protein_coding | tolerated(0.13) | benign(0.017) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| KAT5 | SNV | Missense_Mutation | c.766G>A | p.Asp256Asn | p.D256N | Q92993 | protein_coding | deleterious(0.04) | possibly_damaging(0.479) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| KAT5 | SNV | Missense_Mutation | c.1023G>C | p.Lys341Asn | p.K341N | Q92993 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| KAT5 | SNV | Missense_Mutation | rs199674306 | c.1585N>A | p.Asp529Asn | p.D529N | Q92993 | protein_coding | tolerated(0.09) | possibly_damaging(0.829) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| KAT5 | SNV | Missense_Mutation | c.283N>T | p.Arg95Trp | p.R95W | Q92993 | protein_coding | deleterious(0.04) | probably_damaging(0.975) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| KAT5 | SNV | Missense_Mutation | c.328N>G | p.Thr110Ala | p.T110A | Q92993 | protein_coding | tolerated(0.24) | benign(0.108) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| KAT5 | SNV | Missense_Mutation | rs760709797 | c.911G>A | p.Arg304His | p.R304H | Q92993 | protein_coding | deleterious(0.03) | benign(0.009) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 10524 | KAT5 | TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, ENZYME | inhibitor | 187051791 | ||
| 10524 | KAT5 | TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, ENZYME | ANACARDIC ACID | 22100137 | ||
| 10524 | KAT5 | TRANSCRIPTION FACTOR COMPLEX, TUMOR SUPPRESSOR, ENZYME | 6-DECYLSALICYLIC ACID | CHEMBL416038 | 22100137 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |